Zhang Chenwang, Bai Haowei, Shi Chenkun, Chen Huirong, Li Peng, Huang Yuhua, Chen Huixing, Zhao Fujun, Yao Chencheng, Li Zheng, Zhi Erlei
State Key Laboratory of Reproductive Medicine and Offspring Health, Nanjing Medical University, Nanjing, 211166, China.
Department of Andrology, the Center for Men's Health, Urologic Medical Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, China.
Basic Clin Androl. 2024 Aug 9;34(1):10. doi: 10.1186/s12610-024-00228-z.
Surgical penile prosthesis implantation (PPI) procedures have only recently been introduced to mainland China, with the overall number of such procedures having been conducted to date remaining relatively low. Accordingly, relatively little remains known with respect to the annual trends in PPI. Accordingly, this study was developed with the goal of clarifying these trends across different hospitals in mainland China, while also providing a single-center overview of post-PPI patient outcomes.
To identify males in mainland China who had undergone PPI, a retrospective review of data from January 2019 - October 2023 was conducted. This approach revealed an increase in the total PPI caseload from 120 in 2019 to 413 within the first 10 months of 2023. Over this same interval, the number of surgeons performing PPI rose from 33 to 74. A retrospective review of the 112 patients who had undergone PPI at Shanghai General Hospital from 2019-2023 revealed that these patients had a median age of 39 [27-63] years, and PPI treatment led to a significant increase in median International Index of Erectile Function-5 (IIEF-5) scores from a baseline value of 10.23 ± 1.26 to a post-treatment value of 22.6 ± 2.73. The underlying causes of erectile dysfunction for these patients included vasculogenic factors (58/112; 51.8%), diabetes mellitus (21/112; 18.8%), and injuries to the spinal cord or pelvis (14/112; 12.5%). The overall rates of satisfaction with the PPI reported by patients and their partners were 93.0% and 90.4%, respectively, and the 3-year PPI survival rate for this cohort was 87%.
These data highlight a rising trend in the number of PPI being performed in China, with these steadily increasing rates since 2019 emphasizing the increasingly high levels of acceptance of this procedure by patients and clinicians as a means of treating erectile dysfunction. However, the expertise is restricted to a small number of surgeons. Even so, it is a safe and efficacious approach to managing severe erectile dysfunction for patients in China, and when performed by experienced surgeons based on standardized protocols, low complication rates can be achieved while providing patients and their sexual partners with high levels of satisfaction.
阴茎假体植入手术（PPI）直到最近才被引入中国大陆，迄今为止此类手术的总体数量仍然相对较少。因此，关于PPI的年度趋势了解相对较少。因此，开展本研究的目的是阐明中国大陆不同医院的这些趋势，同时提供PPI术后患者结局的单中心概述。
为了确定中国大陆接受过PPI的男性，对2019年1月至2023年10月的数据进行了回顾性分析。这种方法显示PPI病例总数从2019年的120例增加到2023年前10个月的413例。在同一时期，进行PPI的外科医生数量从33名增加到74名。对2019年至2023年在上海交通大学医学院附属瑞金医院接受PPI的112例患者进行回顾性分析发现，这些患者的中位年龄为39[27 - 63]岁，PPI治疗使国际勃起功能指数-5（IIEF-5）中位评分从基线值10.23±1.26显著提高到治疗后值22.6±2.73。这些患者勃起功能障碍的潜在原因包括血管源性因素（58/112；51.8%）、糖尿病（21/112；18.8%）以及脊髓或骨盆损伤（14/112；12.5%）。患者及其伴侣报告的对PPI的总体满意度分别为93.0%和90.4%，该队列的3年PPI生存率为87%。
这些数据凸显了中国进行PPI手术数量的上升趋势，自2019年以来这些比率稳步上升，强调了患者和临床医生对该手术作为治疗勃起功能障碍手段的接受程度越来越高。然而，专业知识仅限于少数外科医生。即便如此对于中国患者而言，这是一种治疗严重勃起功能障碍的安全有效的方法，并且当由经验丰富的外科医生按照标准化方案进行时，可以实现低并发症发生率，同时为患者及其性伴侣提供高水平的满意度。
